Innovative Research Award
Lawrence Mulligan
Cooper University Hospital and CMSRU, United States
Lawrence J. Mulligan, PhD, FAHA, is a cardiovascular physiology and medical device innovation specialist with more than twenty-five years of experience spanning translational physiology, computational cardiovascular modeling, scientific communications, clinical evidence generation, and cardiovascular technology strategy. His work integrates physiological science, device analytics, computational mechanics, and translational cardiovascular research to support advancement of cardiac technologies and clinical adoption pathways.[1]
Abstract
Lawrence J. Mulligan has contributed to cardiovascular science through work involving computational ventricular mechanics, translational physiology, cardiovascular device analytics, myocardial energetics, electromechanical cardiac behavior, and non-invasive cardiac function assessment. His scientific and leadership activities bridge academia, healthcare institutions, and cardiovascular technology industries, emphasizing evidence generation strategies and scientific advancement supporting cardiovascular innovation.[2]
Keywords
Cardiovascular Physiology; Computational Hemodynamics; Medical Science Liaison; Cardiac Device Innovation; Translational Research; Electromechanical Cardiac Modeling; Heart Failure Therapy; Cardiac Rhythm Management; Clinical Evidence Generation; Cardiovascular Analytics
Introduction
The evolution of cardiovascular medicine increasingly depends upon translational science, computational physiology, and device innovation capable of improving patient outcomes through precision diagnostics and therapeutic technologies. Lawrence J. Mulligan has developed expertise across cardiovascular physiology and medical device strategy while contributing to scientific translation and clinical adoption initiatives associated with cardiac technologies.[3]
Research Profile
- Director of Research, Department of Anesthesiology, Cooper University Healthcare
- Associate Professor, Anesthesiology, Cooper Medical School of Rowan University
- Adjunct Professor, Biomedical Engineering, University of North Dakota
- Former Senior Principal Scientist, Medical Science Liaison, and Technical Fellow at Medtronic
- Fellow of the American Heart Association
- PhD in Cardiac and Systems Physiology from Texas A&M University
Research Contributions
Research contributions by Lawrence J. Mulligan include computational cardiovascular modeling, ventricular mechanics, force-frequency physiology modeling, myocardial efficiency assessment, hemodynamic analytics, cardiac rhythm management science, and translational physiology applications supporting device development and clinical evaluation frameworks.[4]
His work has included development of methodologies focused on non-invasive cardiovascular measurements, vascular aging assessments, myocardial efficiency quantification, ventricular-vascular coupling analysis, and computational approaches informing cardiovascular device innovation and performance evaluation.[5]
Professional leadership activities further include scientific communication programs, key opinion leader engagement strategies, device adoption initiatives, and mentoring programs supporting engineering and medical trainees.
Publications
Publications by Lawrence J. Mulligan, reflect extensive contributions to cardiovascular physiology, computational hemodynamics, cardiac mechanics, and cardiovascular device innovation. His scholarly work focuses on ventricular function, myocardial efficiency, cardiac resynchronization therapy, vascular aging, and non-invasive cardiovascular assessment methodologies. Through peer-reviewed research and translational science, his publications have supported advancements in cardiovascular technology development, clinical decision-making, and evidence-based strategies for improving cardiac device performance and patient outcomes.
Research Impact
Lawrence J. Mulligan’s activities span academic institutions, healthcare systems, and cardiovascular technology industries. Contributions include cardiovascular device analytics development, scientific evidence communication, patent generation, mentoring initiatives, translational physiology leadership, and participation in device-oriented innovation frameworks. Patent contributions include granted and pending intellectual property associated with cardiac sensing, myocardial analytics, electromechanical modeling, and cardiovascular function algorithms.
Research funding involvement exceeds four hundred thousand dollars through grants and research leadership activities spanning cardiovascular physiology and device evaluation domains.
Award Suitability
The academic and scientific portfolio demonstrates characteristics associated with recognition frameworks emphasizing interdisciplinary innovation, translational biomedical science, medical device advancement, intellectual property development, scientific leadership, and evidence-based cardiovascular research contributions. Sustained engagement across healthcare, industry, and academic environments supports consideration within scientific recognition initiatives.
Conclusion
Lawrence J. Mulligan’s work reflects integration of physiology research, computational science, cardiovascular innovation, and translational medical strategy. His professional trajectory demonstrates sustained contributions to cardiovascular technology advancement through scientific leadership, device analytics, translational modeling, and interdisciplinary collaboration supporting cardiovascular medicine and clinical innovation.
External Links
References
- Professional curriculum vitae and academic information supplied for scholarly profile preparation.
- Mulligan LJ. Translational cardiovascular physiology and computational cardiac modeling contributions.
- Cardiovascular innovation leadership and medical device translational science documentation.
- Evaluation of Ventricular-Vascular Coupling with Critical Care Metrics. Physiological Reports, 2024.
- Evaluation of Vascular Aging on Measures of Cardiac Function and Mechanical Efficiency. Frontiers in Cardiovascular Medicine, 2024.